ArticleJournal for immunotherapy of cancer2019
PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8
Article in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 132 citations in OpenAlex.
- Mitochondrial dynamics and T cells immunity in cancer.Biochemistry and biophysics reports · 2026Review
- Mitochondrial metabolism and PD-1 blockade: mechanisms and therapeutic opportunities in cancer immunotherapy.Molecular biology reports · 2026Review
- T-Cell Exhaustion in the Tumor Microenvironment: Subcellular Dysfunction, Pan-Cancer Characteristics, and Therapeutic Interventions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Review
- Review
- Redox index and capacity analysis (RICA) reveals NAD biology changes in T cell responses in vitro and ex vivo.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Review
- Obesity and Cancer: From Systemic Metabolic Reprogramming to Immunotherapy Paradox.Metabolites · 2026Review
- Targeting organelle function in T cells for cancer immunotherapy.Nature reviews. Immunology · 2026Review
- Endometriosis immune microenvironment timing shifts: from immune escape to immune exhaustion.Cell death discovery · 2026Review
- CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead.Frontiers in immunology · 2026Review
- Improving Immune Checkpoint Therapy in the Tumor Microenvironment by Targeting T Cell Metabolism.Endocrine, metabolic & immune disorders drug targets · 2026Review
- Cristae Architecture as a Metabolic Checkpoint in Effector T Cells - Implications for Cancer Immunity.Journal of cancer immunology · 2026Article
- T cell immunometabolic dysfunction in a mouse model of cecal ligation and puncture-induced sepsis.BMC immunology · 2025Article
- Physiological activation of Aryl hydrocarbon receptor by food-derived ligands is essential for the efficacy of anti-PD1 therapy.Nature communications · 2025Article
- Immune cell changes following chemotherapy in advanced pancreatic cancer with variations based on gender.Scientific reports · 2025Article
- Reduced IFN-γ-expressing SARS-CoV-2 specific CD4Scientific reports · 2025Article
- PD-1 expressing islet-specific CD4Immunology and cell biology · 2025Article
- Mitochondrial Metabolism in T-Cell Exhaustion.International journal of molecular sciences · 2025Review
- Pyruvate kinase M2 activation reprograms mitochondria in CD8 T cells, enhancing effector functions and efficacy of anti-PD1 therapy.Cell metabolism · 2025Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundBinding of the programmed death-1 (PD-1) receptor to its ligands (PD-L1/2) transduces inhibitory signals that promote exhaustion of activated T cells. Blockade of the PD-1 pathway is widely used for cancer treatment, yet the inhibitory signals transduced by PD-1 in T cells remain elusive.
methodsExpression profiles of human CD8
resultsPD-1 engagement in human CD8
conclusionsOur results suggest that mitochondria are the main targets of PD-1 inhibitory activity. PD-1 reprograms CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.